Symproic全新购买方式一览

Introduction: Symproic is a peripherally acting μ-opioid receptor antagonist (PAMORA) approved in Japan for the treatment of adults with OIC with cancer and chronic non-cancer pain, and in the United States for the treatment of adults with OIC with chronic non-cancer pain, including patients with chronic pain related to previous cancer or its treatment, who do not require frequent dose increases.

List of new purchase methods for Symproic

The purchase methods mainly include the following channels.

1. Hospital pharmacies: Patients can purchase Symproic in pharmacies of hospitals in countries where Symproic is listed, such as the United States, Japan, etc., which is one of the most common purchase channels. Before purchasing, patients need to prepare a prescription issued by a doctor.

2. Physical pharmacies: The drug may be sold in physical pharmacies in the countries where Symproic is listed, and patients can purchase it after presenting a medical prescription.

3. Medical service institutions: For patients who cannot purchase Symproic in China, they can consider purchasing it through medical service institutions. After placing the order, the drug can be obtained by direct mail.

Please choose the appropriate and formal purchase method according to your own needs, and always ensure that the source of the medicine is legal and of reliable quality. Also understand, side effects, etc.

Symproic Medication Precautions

1. Gastrointestinal perforation: When using Symproic in patients with known or suspected gastrointestinal lesions, the overall risks and benefits should be considered, monitor for severe, persistent or worsening abdominal pain symptoms, and discontinue use when these symptoms occur.

2. Opioid withdrawal: In patients taking Symproic, a cluster of symptoms consistent with opioid withdrawal may occur, including excessive sweating, chills, increased tear secretion, hot flashes, fever, sneezing, feeling cold, abdominal pain, diarrhea, nausea and vomiting.

Drug interactions of Symproic

1. Strong CYP3A inducers: such as rifampicin, may reduce the concentration of naldimedine, and simultaneous use should be avoided.

2. Other opioid antagonists: They may increase the risk of opioid withdrawal and should be avoided when used simultaneously.

3. Moderate and strong CYP3A4 inhibitors: such as fluconazole and itraconazole, may increase the concentration of naldimedine, and adverse reactions should be monitored.

4. P-glycoprotein (P-gp) inhibitors: such as cyclosporine, adverse reactions should be monitored.

Strictly follow your doctor's instructions when using Symproic, and contact a medical professional promptly if any questions arise.